GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (STU:8AK) » Definitions » Cyclically Adjusted Price-to-FCF

Alkermes (STU:8AK) Cyclically Adjusted Price-to-FCF : 277.50 (As of Jun. 07, 2024)


View and export this data going back to . Start your Free Trial

What is Alkermes Cyclically Adjusted Price-to-FCF?

As of today (2024-06-07), Alkermes's current share price is €22.20. Alkermes's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €0.08. Alkermes's Cyclically Adjusted Price-to-FCF for today is 277.50.

The historical rank and industry rank for Alkermes's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

STU:8AK' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 254.47   Med: 539.17   Max: 989.1
Current: 254.47

During the past years, Alkermes's highest Cyclically Adjusted Price-to-FCF was 989.10. The lowest was 254.47. And the median was 539.17.

STU:8AK's Cyclically Adjusted Price-to-FCF is ranked worse than
95.03% of 322 companies
in the Drug Manufacturers industry
Industry Median: 32.255 vs STU:8AK: 254.47

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Alkermes's adjusted free cash flow per share data for the three months ended in Mar. 2024 was €0.068. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €0.08 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alkermes Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Alkermes's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Cyclically Adjusted Price-to-FCF Chart

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 539.22 - 348.13

Alkermes Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 937.21 528.61 348.13 285.12

Competitive Comparison of Alkermes's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Alkermes's Cyclically Adjusted Price-to-FCF falls into.



Alkermes Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Alkermes's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=22.20/0.08
=277.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Alkermes's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.068/120.9901*120.9901
=0.068

Current CPI (Mar. 2024) = 120.9901.

Alkermes Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.014 100.773 0.017
201409 -0.089 100.474 -0.107
201412 0.002 99.576 0.002
201503 -0.054 99.975 -0.065
201506 -0.176 100.573 -0.212
201509 -0.247 100.274 -0.298
201512 -0.084 99.676 -0.102
201603 -0.412 99.676 -0.500
201606 -0.230 101.072 -0.275
201609 0.019 100.274 0.023
201612 -0.014 99.676 -0.017
201703 -0.142 100.374 -0.171
201706 -0.196 100.673 -0.236
201709 0.036 100.474 0.043
201712 0.099 100.075 0.120
201803 -0.238 100.573 -0.286
201806 0.084 101.072 0.101
201809 0.094 101.371 0.112
201812 0.243 100.773 0.292
201903 -0.008 101.670 -0.010
201906 -0.220 102.168 -0.261
201909 0.067 102.268 0.079
201912 0.058 102.068 0.069
202003 -0.344 102.367 -0.407
202006 -0.084 101.769 -0.100
202009 0.287 101.072 0.344
202012 0.320 101.072 0.383
202103 -0.280 102.367 -0.331
202106 0.129 103.364 0.151
202109 0.410 104.859 0.473
202112 0.112 106.653 0.127
202203 0.078 109.245 0.086
202206 -0.071 112.779 -0.076
202209 -0.061 113.504 -0.065
202212 -0.052 115.436 -0.055
202303 -0.159 117.609 -0.164
202306 1.108 119.662 1.120
202309 0.465 120.749 0.466
202312 0.496 120.749 0.497
202403 0.068 120.990 0.068

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alkermes  (STU:8AK) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Alkermes Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Alkermes's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkermes (STU:8AK) Business Description

Industry
Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Alkermes (STU:8AK) Headlines

No Headlines